US-Court Takes Matter of Motion for Preliminary Injunction for Protonix Under Advisement

01.08.2007Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the United States District Court for the District of New Jersey has taken the matter of Wyeth and Nycomed’s motion for a preliminary injunction against Teva Pharmaceuticals USA, Inc. and Sun Pharmaceuticals Inc. in regard to a potential launch of a generic version of Protonix® (pantoprazole sodium) under advisement. The court obtained a commitment from both Teva and Sun not to launch any potential generic version of pantoprazole before September 7, 2007 while it considers the matter.

ALTANA Pharma AG, acquired by Nycomed at the beginning of this year, and Wyeth sued Teva and Sun for patent infringement based on Teva’s and Sun’s filing of Abbreviated New Dug Applications (ANDAs) seeking U.S. Food and Drug Administration (FDA) approval to market generic versions of Protonix® before the patent for pantoprazole, the active ingredient in Protonix®, expires on July 19, 2010.

Under the Hatch-Waxman act, the filing of the lawsuit stayed final FDA approval of Teva’s ANDA until August 2, 2007, and Sun’s ANDA until September 8, 2007.  In anticipation of the end of those stays, Nycomed and Wyeth filed a motion for preliminary injunction to stop any potential launch.

About Nycomed

Nycomed provides products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets.

The company is active within a range of therapeutic areas, including cardiology, gastroenterology, osteoporosis, respiratory, pain and tissue management. New products are sourced both from own research and from external partners. Operating throughout Europe and in fast-growing markets such as Latin America, Russia/CIS and the Asia-Pacific region Nycomed has a presence in about 50 markets worldwide.

Privately owned, the combined group had non-audited estimated annual sales of approximately € 3.4 billion and an EBITDA of € 933.4 million (2006 results).

For more information visit www.nycomed.com


For further information

International:
Christoffer Jensen, VP Communications
Phone: +45 46 77 11 12
Mobile: +45 22 43 69 44

Germany:
Susanne Hof, Head of External Communications
Phone: +49 7531 84 30 59
Mobile: +49 151 55 00 26 65

 

 

For further information

Media:
General phone:

+41 44 555 15 10
Beatrix Benz,

phone: +41 44 555 1508
Tobias Cottmann,

phone: +41 44 555 1501

Investors:
Christian B. Seidelin,

phone: +41 44 555 11 04

Related information


English PDF
German PDF

Top of page

Takeda Pharma